梅毒血清固定临床管理专家共识（2023）

doi:10.35541/cjd.20220656

中华皮肤科杂志 ›› 2023, Vol. 56 ›› Issue (5): 383-388.doi: 10.35541/cjd.20220656

梅毒血清固定临床管理专家共识（2023）

中国医师协会皮肤科医师分会性传播疾病专业委员会

中国医师协会皮肤科医师分会性传播疾病专业委员会

收稿日期:2022-09-14 修回日期:2022-11-15 发布日期:2023-05-04
通讯作者: 周平玉；徐金华；王千秋 E-mail:zhoupingyu@medmail.com.cn; xjhhsyy@163.com; doctorwqq@163.com

Expert consensus on clinical management of serofast state in syphilis （2023）

Committee on Sexually Transmitted Diseases, China Dermatologist Association

Committee on Sexually Transmitted Diseases, China Dermatologist Association

Received:2022-09-14 Revised:2022-11-15 Published:2023-05-04
Contact: Zhou Pingyu; Xu Jinhua; Wang Qianqiu E-mail:zhoupingyu@medmail.com.cn; xjhhsyy@163.com; doctorwqq@163.com

摘要/Abstract

摘要： 【摘要】梅毒血清固定是指梅毒患者经过正规驱梅治疗后临床症状消失，但非梅毒螺旋体抗原血清试验持续不转阴的一种特殊血清学现象。梅毒血清固定的正确判断在临床上事关过度治疗和/或相对治疗不足。为进一步认识梅毒血清固定并建立和完善梅毒血清固定临床管理方案，解决临床医生对梅毒血清固定的疑惑，减轻梅毒血清固定人群的心理负担、改善其生活质量，中国医师协会皮肤科医师分会性传播疾病专业委员会组织国内有关专家研讨，在梅毒血清固定的定义、流行病学、可能的相关因素及规范化管理等方面达成共识。

关键词: 梅毒, 梅毒血清诊断, 梅毒血清固定, 非梅毒螺旋体抗原血清试验

Abstract: 【Abstract】 Serofast state in syphilis refers to a special serological reaction in syphilis patients, whose clinical symptoms have disappeared after regular anti-syphilitic treatment, but the non-Treponema pallidum antigen-based serologic test remains positive. Accurate estimation of serofast state in syphilis is important for the avoidance of overtreatment and/or relative undertreatment in clinical practice. In order to further understand the serofast state in syphilis, establish and improve its clinical management strategies, solve clinicians′ doubts about serofast syphilis, and reduce the psychological burden and improve the quality of life of the population with serofast syphilis, the Committee on Sexually Transmitted Diseases, China Dermatologist Association organized relevant Chinese experts to discuss and reach a consensus on the definition, epidemiological features, possible relevant factors and standardized management of serofast state in syphilis.

Key words: Syphilis, Syphilis serodiagnosis, Syphilis serofast, Non-Treponema pallidum antigen serologic test

中国医师协会皮肤科医师分会性传播疾病专业委员会. 梅毒血清固定临床管理专家共识（2023）[J]. 中华皮肤科杂志, 2023,56(5):383-388. doi:10.35541/cjd.20220656

Committee on Sexually Transmitted Diseases, China Dermatologist Association. Expert consensus on clinical management of serofast state in syphilis （2023）[J]. Chinese Journal of Dermatology, 2023, 56(5): 383-388.doi:10.35541/cjd.20220656

参考文献 41

［1］	O′Byrne P, MacPherson P. Syphilis［J］. BMJ, 2019,365:l4159. doi: 10.1136/bmj.l4159.
［2］	Lafond RE, Lukehart SA. Biological basis for syphilis［J］. Clin Microbiol Rev, 2006,19（1）:29⁃49. doi: 10.1128/CMR.19.1.29⁃49.2006.
［3］	Janier M, Unemo M, Dupin N, et al. 2020 European guideline on the management of syphilis［J］. J Eur Acad Dermatol Venereol, 2021,35（3）:574⁃588. doi: 10.1111/jdv.16946.
［4］	Tuddenham S, Katz SS, Ghanem KG. Syphilis laboratory guidelines: performance characteristics of nontreponemal antibody tests［J］. Clin Infect Dis, 2020,71（Suppl 1）:S21⁃S42. doi: 10.1093/cid/ciaa306.
［5］	Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021［J］. MMWR Recomm Rep, 2021,70（4）:1⁃187. doi: 10.15585/mmwr.rr7004a1.
［6］	中国中西医结合学会皮肤性病专业委员会性病学组. 梅毒血清固定临床处理专家共识［J］. 中华皮肤科杂志, 2015,48（11）:753⁃755. doi: 10.3760/cma.j.issn.0412⁃4030.2015.11.001.
［7］	周平玉. 梅毒血清固定再认识［J］. 中华皮肤科杂志, 2017,50（5）:379⁃381. doi: 10.3760/cma.j.issn.0412⁃4030.2017.05.021.
［8］	Moore JE. The Modern Treatment of Syphilis［M］. Baltimore: MD: Charles C Thomas Publisher, 1933.
［9］	Ghanem KG, Hook EW 3rd. The Terms "Serofast" and "Serological Nonresponse" in the modern syphilis era［J］. Sex Transm Dis, 2021,48（6）:451⁃452. doi: 10.1097/OLQ.000000000 0001387.
［10］	Seña AC, Wolff M, Behets F, et al. Response to therapy following retreatment of serofast early syphilis patients with benzathine penicillin［J］. Clin Infect Dis, 2013,56（3）:420⁃422. doi: 10.1093/cid/cis918.
［11］	李淑莲, 林志锋, 张惠姗, 等. 梅毒血清固定与神经梅毒的关系［J］. 中华医院感染学杂志, 2012,22（10）:2235⁃2238.
［12］	Zhou P, Gu X, Lu H, et al. Re⁃evaluation of serological criteria for early syphilis treatment efficacy: progression to neurosyphilis despite therapy［J］. Sex Transm Infect, 2012,88（5）:342⁃345. doi: 10.1136/sextrans⁃2011⁃050247.
［13］	Clement ME, Okeke NL, Hicks CB. Treatment of syphilis: a systematic review［J］. JAMA, 2014,312（18）:1905⁃1917. doi: 10.1001/jama.2014.13259.
［14］	刘焕颜, 梁晓冬, 邓婕, 等. 梅毒血清固定的产生及临床转归［J］. 中国麻风皮肤病杂志, 2019,35（10）:637⁃640.
［15］	Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015［J］. MMWR Recomm Rep, 2015,64（RR⁃03）:1⁃137.
［16］	Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021［J］. MMWR Recomm Rep, 2021,70（4）:1⁃187. doi: 10.15585/mmwr.rr7004a1.
［17］	Tong ML, Lin LR, Liu GL, et al. Factors associated with serological cure and the serofast state of HIV⁃negative patients with primary, secondary, latent, and tertiary syphilis［J］. PLoS One, 2013,8（7）:e70102. doi: 10.1371/journal.pone.0070102.
［18］	Lin LR, Zheng WH, Tong ML, et al. Further evaluation of the characteristics of Treponema pallidum⁃specific IgM antibody in syphilis serofast reaction patients［J］. Diagn Microbiol Infect Dis, 2011,71（3）:201⁃207. doi: 10.1016/j.diagmicrobio.2011.07. 005.
［19］	杨文林, 杨健, 黄新宇. 近10年梅毒血清固定患者临床分析［J］. 临床皮肤科杂志, 2005,34（11）:719⁃721. doi: 10.3969/j.issn.1000⁃4963.2005.11.002.
［20］	Shi M, Peng RR, Gao Z, et al. Risk profiles of neurosyphilis in HIV⁃negative patients with primary, secondary and latent syphilis: implications for clinical intervention［J］. J Eur Acad Dermatol Venereol, 2016,30（4）:659⁃666. doi: 10.1111/jdv.13514.
［21］	Radolf JD, Deka RK, Anand A, et al. Treponema pallidum, the syphilis spirochete: making a living as a stealth pathogen［J］. Nat Rev Microbiol, 2016,14（12）:744⁃759. doi: 10.1038/nrmicro. 2016.141.
［22］	Radolf JD, Kumar S. The Treponema pallidum outer membrane［J］. Curr Top Microbiol Immunol, 2018,415:1⁃38. doi: 10.1007/82_2017_44.
［23］	Ovchinnikov NM. Immunity in syphilis［J］. Vestn Dermatol Venerol, 1973,47（3）:36⁃42.
［24］	Sell S, Norris SJ. The biology, pathology, and immunology of syphilis［J］. Int Rev Exp Pathol, 1983,24:203⁃276.
［25］	Yu Q, Cheng Y, Wang Y, et al. Aberrant humoral immune responses in neurosyphilis: CXCL13/CXCR5 play a pivotal role for B⁃cell recruitment to the cerebrospinal fluid［J］. J Infect Dis, 2017,216（5）:534⁃544. doi: 10.1093/infdis/jix233.
［26］	Li K, Wang C, Lu H, et al. Regulatory T cells in peripheral blood and cerebrospinal fluid of syphilis patients with and without neurological involvement［J］. PLoS Negl Trop Dis, 2013,7（11）:e2528. doi: 10.1371/journal.pntd.0002528.
［27］	Wang C, Zhu L, Gao Z, et al. Increased interleukin⁃17 in peripheral blood and cerebrospinal fluid of neurosyphilis patients［J］. PLoS Negl Trop Dis, 2014,8（7）:e3004. doi: 10. 1371/journal.pntd.0003004.
［28］	Pastuszczak M, Gozdzialska A, Jakiela B, et al. Robust pro⁃inflammatory immune response is associated with serological cure in patients with syphilis: an observational study［J］. Sex Transm Infect, 2017,93（1）:11⁃14. doi: 10.1136/sextrans⁃2016⁃052681.
［29］	Pastuszczak M, Jakiela B, Wojas⁃Pelc A. Association of interleukin⁃10 promoter polymorphisms with serofast state after syphilis treatment［J］. Sex Transm Infect, 2019,95（3）:163⁃168. doi: 10.1136/sextrans⁃2018⁃053753.
［30］	Kojima N, Siebert JC, Maecker H, et al. The application of cytokine expression assays to differentiate active from previously treated syphilis［J］. J Infect Dis, 2020,222（4）:690⁃694. doi: 10.1093/infdis/jiaa127.
［31］	应作霖, 王丰. 梅毒患者血清固定临床分析［J］. 皮肤病与性病, 2012,34（2）:106,110. doi: 10.3969/j.issn.1002⁃1310.2012. 02.022.
［32］	赵玉磊, 乐文静, 朱晓凤, 等. 梅毒患者治疗后血清学转归的影响因素探讨［J］. 国际皮肤性病学杂志, 2014,40（3）:146⁃148. doi: 10.3760/cma.j.issn.1673⁃4173.2014.03.002.
［33］	Ren RX, Wang LN, Zheng HY, et al. No improvement in serological response among serofast latent patients retreated with benzathine penicillin［J］. Int J STD AIDS, 2016,27（1）:58⁃62. doi: 10.1177/0956462415573677.
［34］	Romanowski B, Sutherland R, Fick GH, et al. Serologic response to treatment of infectious syphilis［J］. Ann Intern Med, 1991,114（12）:1005⁃1009. doi: 10.7326/0003⁃4819⁃114⁃12⁃1005.
［35］	Fiumara NJ. Serologic responses to treatment of 128 patients with late latent syphilis［J］. Sex Transm Dis, 1979,6（4）:243⁃246. doi: 10.1097/00007435⁃197910000⁃00003.
［36］	中国疾病预防控制中心性病控制中心中华医学会皮肤性病学分会性病学组中国医师协会皮肤科医师分会性病亚专业委员会. 梅毒、淋病和生殖道沙眼衣原体感染诊疗指南（2020年）［J］. 中华皮肤科杂志, 2020,53（3）:168⁃179. doi:10.35541/cjd.20190808
［37］	Libois A, De Wit S, Poll B, et al. HIV and syphilis: when to perform a lumbar puncture［J］. Sex Transm Dis, 2007,34（3）:141⁃144. doi: 10.1097/01.olq.0000230481.28936.e5.
［38］	Rotman L, Luo X, Thompson A, et al. Risk of neurosyphilis in HIV⁃infected persons with syphilis lacking signs or symptoms of central nervous system infection［J］. HIV Med, 2019,20（1）:27⁃32. doi: 10.1111/hiv.12677.
［39］	Zhou P, Gu Z, Xu J, et al. A study evaluating ceftriaxone as a treatment agent for primary and secondary syphilis in pregnancy［J］. Sex Transm Dis, 2005,32（8）:495⁃498. doi: 10.1097/01.olq. 0000170443.70739.cd.
［40］	Hong FC, Wu XB, Yang F, et al. Risk of congenital syphilis （CS） following treatment of maternal syphilis: results of a CS control program in China［J］. Clin Infect Dis, 2017,65（4）:588⁃594. doi: 10.1093/cid/cix371.
［41］	国家卫生计生委办公厅. 预防艾滋病、梅毒和乙肝母婴传播工作实施方案（2015年版）.2015⁃04⁃09.

[1]	沈云良曾凡荣孔文明吴李梅费丽娟. 浙江省2016—2020年梅毒流行时空特征分析[J]. 中华皮肤科杂志, 2022, 55(3): 219-223.
[2]	王娟娟陈容季江苏文星魏钰倩赵莹尹兴平苏玉华施辛. 以精神行为异常为首发症状的67例神经梅毒患者回顾性分析[J]. 中华皮肤科杂志, 2022, 55(3): 231-234.
[3]	岳晓丽龚向东李婧张家晖. 2014—2019年中国梅毒流行趋势与特征分析[J]. 中华皮肤科杂志, 2021, 54(8): 668-672.
[4]	陈森红杨斌. 梅毒螺旋体血行播散机制的研究进展[J]. 中华皮肤科杂志, 2021, 54(6): 545-548.
[5]	卢改会李涛刘学伟. 苄星青霉素联合头孢曲松对早期梅毒血清快速血浆反应素环状卡片试验/甲苯胺红不加热血清试验结果影响的Meta分析[J]. 中华皮肤科杂志, 2021, 54(6): 522-526.
[6]	李可王千秋龙福泉. 神经梅毒发病的危险因素及预测因素研究进展[J]. 中华皮肤科杂志, 2021, 54(5): 459-462.
[7]	王千秋杜方智张栩张瑞丽 . 神经梅毒研究现状及防治策略探索[J]. 中华皮肤科杂志, 2021, 54(11): 951-954.
[8]	巩慧子王涛郑和义李军. 二期梅毒41例免疫组化特征分析[J]. 中华皮肤科杂志, 2021, 54(10): 884-887.
[9]	魏然柯吴坚陈文韬谭玲俏刘雅慧吕萍黄涛张君张晓辉王柳苑车雅敏. 基于TP0136蛋白异质性建立一种新的苍白密螺旋体分子分型方法[J]. 中华皮肤科杂志, 2020, 53(7): 546-550.
[10]	中国疾病预防控制中心性病控制中心中华医学会皮肤性病学分会性病学组中国医师协会皮肤科医师分会性病亚专业委员会. 梅毒、淋病和生殖道沙眼衣原体感染诊疗指南（2020年）[J]. 中华皮肤科杂志, 2020, 53(3): 168-179.
[11]	汤华阳高金平郭泽魏瑾樊娇娇唐先发王培光孔晓明杨森. 131例神经梅毒患者临床特征及实验室检查结果分析[J]. 中华皮肤科杂志, 2020, 53(10): 774-780.
[12]	柯吴坚黄涛张君吕萍薛耀华张晓辉王柳苑刘雅慧郑和平. 广东地区梅毒螺旋体临床株的分离传代培养及非同义单核苷酸多态性检测[J]. 中华皮肤科杂志, 2018, 51(5): 366-368.
[13]	韩燕魏万惠尹跃平 David Anderson 王红春 Mary L Gacia Huy Van 朱小宇陈凯陈祥生. 梅毒IgA快速检测试剂诊断早期现症梅毒的应用性评估[J]. 中华皮肤科杂志, 2018, 51(5): 372-375.
[14]	吴凡胡文龙许卜方王千秋. 梅毒螺旋体对人脑微血管内皮细胞趋化因子配体6、8、10表达的影响[J]. 中华皮肤科杂志, 2018, 51(5): 358-362.
[15]	王雅洁龚向东岳晓丽李婧. 中国2010年和2015年胎传梅毒空间分布特征[J]. 中华皮肤科杂志, 2018, 51(5): 337-340.

梅毒血清固定临床管理专家共识（2023）

Expert consensus on clinical management of serofast state in syphilis （2023）

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 41

相关文章 15

Metrics

本文评价

推荐阅读 10